{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T20:51:54Z","timestamp":1793393514194,"version":"4.5.0"},"update-to":[{"DOI":"10.1002\/14651858.cd007076.pub2","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2019,1,23]],"date-time":"2019-01-23T00:00:00Z","timestamp":1548201600000}}],"reference-count":208,"publisher":"Wiley","issue":"5","content-domain":{"domain":["wiley.com","cochranelibrary.com"],"crossmark-restriction":true},"short-container-title":[],"DOI":"10.1002\/14651858.cd007076.pub3","type":"journal-article","created":{"date-parts":[[2019,1,24]],"date-time":"2019-01-24T18:02:28Z","timestamp":1548352948000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":165,"title":["Pregabalin for neuropathic pain in adults"],"prefix":"10.1002","volume":"2019","author":[{"given":"Sheena","family":"Derry","sequence":"first","affiliation":[{"name":"Oxford Oxfordshire UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rae Frances","family":"Bell","sequence":"additional","affiliation":[{"name":"Haukeland University Hospital; Regional Centre of Excellence in Palliative Care; Bergen Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sebastian","family":"Straube","sequence":"additional","affiliation":[{"name":"University of Alberta; Department of Medicine, Division of Preventive Medicine; 5-30 University Terrace 8303-112 Street Edmonton AB Canada T6G 2T4"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philip J","family":"Wiffen","sequence":"additional","affiliation":[{"name":"Thame UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dominic","family":"Aldington","sequence":"additional","affiliation":[{"name":"Royal Hampshire County Hospital; Winchester UK SO22 5DG"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R Andrew","family":"Moore","sequence":"additional","affiliation":[{"name":"Plymouth UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2019,1,23]]},"reference":[{"key":"10.1002\/14651858.CD007076.pub3-BIB0001|cit1","unstructured":"Pfizer (Sponsor) None known WC500046600_EMEA found at http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Scientific_Discussion\/human\/000546\/WC500046600.pdf"},{"key":"10.1002\/14651858.CD007076.pub3-BIB0002|cit2","unstructured":"Pfizer (Sponsor) None known WC500046600_EMEA found at http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Scientific_Discussion\/human\/000546\/WC500046600.pdfWC500046600_EMEA"},{"key":"10.1002\/14651858.CD007076.pub3-BIB0003|cit3","doi-asserted-by":"publisher","first-page":"257","DOI":"10.2147\/JPR.S78303","article-title":"Predictors of placebo response in peripheral neuropathic pain: insights from pregabalin clinical trials","volume":"8","author":"Freeman","year":"2015","journal-title":"Journal of Pain Research"},{"issue":"2","key":"10.1002\/14651858.CD007076.pub3-BIB0004|cit4","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1016\/j.pain.2009.09.017","article-title":"How do changes in pain severity levels correspond to changes in health status and function in patients with painful diabetic peripheral neuropathy?","volume":"149","author":"Hoffman","year":"2010","journal-title":"Pain"},{"key":"10.1002\/14651858.CD007076.pub3-BIB0005|cit5","unstructured":"NCT00156078 A 14-week, double-blind, randomized, placebo-controlled, multicenter study to evaluate the safety and efficacy of pregabalin (150 mg-600 mg\/day) using a flexible optimal dose schedule in patients with painful diabetic peripheral neuropathy (DPN) www.clinicaltrials.gov\/ct2\/show\/NCT00156078"},{"key":"10.1002\/14651858.CD007076.pub3-BIB0006|cit6","unstructured":"Anon A randomized double-blind, placebo-controlled, parallel-group, multi-center trial of pregabalin versus placebo in the treatment of neuropathic pain associated with diabetic peripheral neuropathy PhRMA Clinical Study Synopsis"},{"key":"10.1002\/14651858.CD007076.pub3-BIB0007|cit7","unstructured":"Anon A randomized, double-blind, placebo-controlled, parallel-group, multicenter trial of pregabalin versus placebo in the treatment of neuropathic pain associated with HIV neuropathy. 2014 pfizer.com\/science\/research_clinical_trials\/trial_results (accessed 12 June 2017)"},{"key":"10.1002\/14651858.CD007076.pub3-BIB0008|cit8","unstructured":"Anon A randomized double blind placebo controlled parallel group study of the efficacy and safety of pregabalin (BID) in subjects with post-traumatic peripheral neuropathic pain. 2016 pfizer.com\/science\/research_clinical_trials\/trial_results (accessed 12 June 2017)"},{"key":"10.1002\/14651858.CD007076.pub3-BIB0009|cit9","unstructured":"Anon A randomized, double blind, placebo controlled, 2-way crossover methodology study designed to assess the reproducibility and sensitivity of quantitative sensory testing (QST) in patients with neuropathic pain treated with pregabalin vs placebo. 2010 pfizer.com\/science\/research_clinical_trials\/trial_results (accessed 12 June 2017)"},{"key":"10.1002\/14651858.CD007076.pub3-BIB0010|cit10","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1186\/1471-2377-8-33","article-title":"Efficacy and safety of pregabalin 600 mg\/d for treating painful diabetic peripheral neuropathy: a double-blind placebo-controlled trial","volume":"8","author":"Arezzo","year":"2008","journal-title":"BMC Neurology"},{"issue":"10","key":"10.1002\/14651858.CD007076.pub3-BIB0011|cit11","doi-asserted-by":"publisher","first-page":"1019","DOI":"10.1111\/j.1464-5491.2009.02806.x","article-title":"Amitriptyline vs. pregabalin in painful diabetic neuropathy: a randomized double blind clinical trial","volume":"26","author":"Bansal","year":"2009","journal-title":"Diabetic Medicine"},{"issue":"3","key":"10.1002\/14651858.CD007076.pub3-BIB0012|cit12","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1016\/j.pain.2010.04.013","article-title":"The efficacy and safety of pregabalin in the treatment of neuropathic pain associated with chronic lumbosacral radiculopathy","volume":"150","author":"Baron","year":"2010","journal-title":"Pain"},{"issue":"6","key":"10.1002\/14651858.CD007076.pub3-BIB0013|cit13","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1212\/WNL.0b013e318281546b","article-title":"A randomized trial of pregabalin in patients with neuropathic pain due to spinal cord injury","volume":"80","author":"Cardenas","year":"2013","journal-title":"Neurology"},{"issue":"2","key":"10.1002\/14651858.CD007076.pub3-BIB0014|cit14","doi-asserted-by":"publisher","first-page":"e57","DOI":"10.1111\/ajco.12311","article-title":"Efficacy and safety of pregabalin in patients with neuropathic cancer pain undergoing morphine therapy","volume":"13","author":"Dou","year":"2017","journal-title":"Asia-Pacific Journal of Clinical Oncology"},{"key":"10.1002\/14651858.CD007076.pub3-BIB0015|cit15","doi-asserted-by":"crossref","first-page":"1274","DOI":"10.1212\/01.WNL.0000055433.55136.55","article-title":"Pregabalin for the treatment of postherpetic neuralgia: a randomized, placebo-controlled trial","volume":"60","author":"Dworkin","year":"2003","journal-title":"Neurology"},{"key":"10.1002\/14651858.CD007076.pub3-BIB0016|cit16","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1007\/s00482-005-0449-0","article-title":"Effectiveness and time to onset of pregabalin in patients with neuropathic pain","volume":"20","author":"Freyhagen","year":"2006","journal-title":"Schmerz"},{"key":"10.1002\/14651858.CD007076.pub3-BIB0017|cit17","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1016\/j.pain.2005.02.032","article-title":"Efficacy of pregabalin in neuropathic pain evaluated in a 12-week, randomised, double-blind, multicentre, placebo-controlled trial of flexible- and fixed-dose regimens","volume":"115","author":"Freynhagen","year":"2005","journal-title":"Pain"},{"issue":"3","key":"10.1002\/14651858.CD007076.pub3-BIB0018|cit18","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1097\/AJP.0b013e3181fe13f6","article-title":"Pregabalin for peripheral neuropathic pain: a multicenter, enriched enrollment randomized withdrawal placebo-controlled trial","volume":"27","author":"Gilron","year":"2011","journal-title":"Clinical Journal of Pain"},{"issue":"11","key":"10.1002\/14651858.CD007076.pub3-BIB0019|cit19","doi-asserted-by":"publisher","first-page":"927","DOI":"10.1097\/AJP.0000000000000339","article-title":"The efficacy of pregabalin in the treatment of prediabetic neuropathic pain","volume":"32","author":"Gonz\u00e1lez-Duarte","year":"2016","journal-title":"Clinical Journal of Pain"},{"issue":"2","key":"10.1002\/14651858.CD007076.pub3-BIB0020|cit20","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1016\/j.clinthera.2011.02.007","article-title":"Efficacy of pregabalin for peripheral neuropathic pain: results of an 8-week, flexible-dose, double-blind, placebo-controlled study conducted in China","volume":"33","author":"Guan","year":"2011","journal-title":"Clinical Therapeutics"},{"issue":"3","key":"10.1002\/14651858.CD007076.pub3-BIB0021|cit21","doi-asserted-by":"publisher","first-page":"514","DOI":"10.1016\/j.pain.2010.10.050","article-title":"Impact of responder definition on the enriched enrollment randomized withdrawal trial design for establishing proof of concept in neuropathic pain","volume":"152","author":"Hewitt","year":"2011","journal-title":"Pain"},{"issue":"5","key":"10.1002\/14651858.CD007076.pub3-BIB0022|cit22","doi-asserted-by":"publisher","first-page":"958","DOI":"10.1097\/j.pain.0000000000000143","article-title":"Imipramine and pregabalin combination for painful polyneuropathy: a randomized controlled trial","volume":"156","author":"Holbech","year":"2015","journal-title":"Pain"},{"issue":"11","key":"10.1002\/14651858.CD007076.pub3-BIB0023|cit23","doi-asserted-by":"publisher","first-page":"946","DOI":"10.1097\/AJP.0000000000000198","article-title":"Efficacy and safety of pregabalin in the treatment of patients with painful diabetic peripheral neuropathy and pain on walking","volume":"31","author":"Huffman","year":"2015","journal-title":"Clinical Journal of Pain"},{"issue":"7","key":"10.1002\/14651858.CD007076.pub3-BIB0024|cit24","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1097\/AJP.0000000000000445","article-title":"Efficacy and safety of once-daily controlled-release pregabalin for the treatment of patients with postherpetic neuralgia: a double-blind, randomized withdrawal, placebo-controlled trial","volume":"33","author":"Huffman","year":"2017","journal-title":"Clinical Journal of Pain"},{"issue":"5","key":"10.1002\/14651858.CD007076.pub3-BIB0025|cit25","doi-asserted-by":"publisher","first-page":"1018","DOI":"10.1016\/j.pain.2010.12.023","article-title":"Safety and efficacy of pregabalin in patients with central post-stroke pain","volume":"152","author":"Kim","year":"2011","journal-title":"Pain"},{"key":"10.1002\/14651858.CD007076.pub3-BIB0026|cit26","doi-asserted-by":"crossref","first-page":"2104","DOI":"10.1212\/01.WNL.0000145767.36287.A1","article-title":"Pregabalin relieves symptoms of painful diabetic neuropathy: a randomized controlled trial","volume":"63","author":"Lesser","year":"2004","journal-title":"Neurology"},{"issue":"1","key":"10.1002\/14651858.CD007076.pub3-BIB0027|cit27","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1111\/papr.12413","article-title":"A randomized, double-blind, placebo-controlled trial to evaluate the efficacy and safety of pregabalin for postherpetic neuralgia in a population of Chinese patients","volume":"17","author":"Liu","year":"2017","journal-title":"Pain Practice"},{"issue":"3","key":"10.1002\/14651858.CD007076.pub3-BIB0028|cit28","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1177\/1049909111412539","article-title":"A comparative efficacy of amitriptyline, gabapentin, and pregabalin in neuropathic cancer pain: a prospective randomized double-blind placebo-controlled study","volume":"29","author":"Mishra","year":"2012","journal-title":"American Journal of Hospice and Palliative Care"},{"issue":"14","key":"10.1002\/14651858.CD007076.pub3-BIB0029|cit29","doi-asserted-by":"publisher","first-page":"2370","DOI":"10.1016\/j.clinthera.2011.01.014","article-title":"Efficacy and tolerability of pregabalin using a flexible, optimized dose schedule in Korean patients with peripheral neuropathic pain: a 10-week, randomized, double-blind, placebo-controlled, multicenter study","volume":"32","author":"Moon","year":"2010","journal-title":"Clinical Therapeutics"},{"issue":"3","key":"10.1002\/14651858.CD007076.pub3-BIB0030|cit30","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1111\/1753-0407.12585","article-title":"Efficacy and safety of pregabalin for painful diabetic peripheral neuropathy in a population of Chinese patients: a randomized placebo-controlled trial","volume":"10","author":"Mu","year":"2018","journal-title":"Journal of Diabetes"},{"key":"10.1002\/14651858.CD007076.pub3-BIB0031|cit31","unstructured":"NCT00785577 A phase 2 study of the effects of LY545694, an iGluR5 antagonist, in the treatment of subjects with painful diabetic neuropathy clinicaltrials.gov\/ct2\/show\/NCT00785577 (accessed 13 February 2018)"},{"issue":"2","key":"10.1002\/14651858.CD007076.pub3-BIB0032|cit32","first-page":"141","article-title":"Evaluation of the efficacy and safety of pregabalin in the treatment of postherpetic neuralgia: a randomized, double-blind, multicenter, placebo-controlled study","volume":"17","author":"Ogawa","year":"2010","journal-title":"Journal of Japan Society of Pain Clinicians"},{"issue":"5","key":"10.1002\/14651858.CD007076.pub3-BIB0033|cit33","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1097\/AJP.0b013e31829ea1a1","article-title":"Pregabalin in patients with inadequately treated painful diabetic peripheral neuropathy: a randomized withdrawal trial","volume":"30","author":"Raskin","year":"2014","journal-title":"Clinical Journal of Pain"},{"issue":"3","key":"10.1002\/14651858.CD007076.pub3-BIB0034|cit34","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1097\/AJP.0000000000000254","article-title":"Pregabalin in patients with painful diabetic peripheral neuropathy using an NSAID for other pain conditions: a double-blind crossover study","volume":"32","author":"Raskin","year":"2016","journal-title":"Clinical Journal of Pain"},{"issue":"6","key":"10.1002\/14651858.CD007076.pub3-BIB0035|cit35","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1111\/papr.12014","article-title":"A randomized, controlled trial of gabapentin enacarbil in subjects with neuropathic pain associated with diabetic peripheral neuropathy","volume":"13","author":"Rauck","year":"2013","journal-title":"Pain Practice"},{"issue":"4","key":"10.1002\/14651858.CD007076.pub3-BIB0036|cit36","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1016\/j.jpain.2004.12.007","article-title":"Relief of painful diabetic peripheral neuropathy with pregabalin: a randomized, placebo-controlled trial","volume":"6","author":"Richter","year":"2005","journal-title":"Journal of Pain"},{"key":"10.1002\/14651858.CD007076.pub3-BIB0037|cit37","doi-asserted-by":"publisher","first-page":"628","DOI":"10.1016\/j.pain.2004.05.001","article-title":"Pregabalin for the treatment of painful diabetic peripheral neuropathy: a double-blind, placebo-controlled trial","volume":"110","author":"Rosenstock","year":"2004","journal-title":"Pain"},{"key":"10.1002\/14651858.CD007076.pub3-BIB0038|cit38","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1016\/j.pain.2004.01.001","article-title":"Pregabalin reduces pain and improves sleep and mood disturbances in patients with post-herpetic neuralgia: results of a randomised, placebo-controlled clinical trial","volume":"109","author":"Sabatowski","year":"2004","journal-title":"Pain"},{"issue":"1","key":"10.1002\/14651858.CD007076.pub3-BIB0039|cit39","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1111\/j.1464-5491.2010.03152.x","article-title":"Efficacy and safety of pregabalin for treating neuropathic pain associated with diabetic peripheral neuropathy: a 14 week, randomized, double-blind, placebo-controlled trial","volume":"28","author":"Satoh","year":"2011","journal-title":"Diabetic Medicine"},{"key":"10.1002\/14651858.CD007076.pub3-BIB0040|cit40","doi-asserted-by":"publisher","first-page":"1792","DOI":"10.1212\/01.wnl.0000244422.45278.ff","article-title":"Pregabalin in central neuropathic pain associated with spinal cord injury: a placebo-controlled trial","volume":"67","author":"Siddall","year":"2006","journal-title":"Neurology"},{"issue":"5","key":"10.1002\/14651858.CD007076.pub3-BIB0041|cit41","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1212\/WNL.0b013e3181ccc6ef","article-title":"Pregabalin for painful HIV neuropathy: a randomized, double-blind, placebo-controlled trial","volume":"74","author":"Simpson","year":"2010","journal-title":"Neurology"},{"issue":"4","key":"10.1002\/14651858.CD007076.pub3-BIB0042|cit42","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1111\/papr.12080","article-title":"Efficacy and safety of carisbamate in patients with diabetic neuropathy or postherpetic neuralgia: results from 3 randomized, double-blind placebo-controlled trials","volume":"14","author":"Smith","year":"2014","journal-title":"Pain Practice"},{"issue":"11","key":"10.1002\/14651858.CD007076.pub3-BIB0043|cit43","doi-asserted-by":"publisher","first-page":"1006","DOI":"10.1016\/j,pain.2008.05.014","article-title":"Pregabalin for postherpetic neuralgia: placebo-controlled trial of fixed and flexible dosing regimens on allodynia and time to onset of pain relief","volume":"9","author":"Stacey","year":"2008","journal-title":"Journal of Pain"},{"issue":"2","key":"10.1002\/14651858.CD007076.pub3-BIB0044|cit44","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1016\/j.ejpain.2007.05.003","article-title":"Pregabalin for relief of neuropathic pain associated with diabetic neuropathy: a randomized, double-blind study","volume":"12","author":"T\u00f6lle","year":"2008","journal-title":"European Journal of Pain"},{"issue":"2","key":"10.1002\/14651858.CD007076.pub3-BIB0045|cit45","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1185\/030079906X80404","article-title":"Efficacy and tolerability of twice-daily pregabalin for treating pain and related sleep interference in postherpetic neuralgia: a 13-week, randomized trial","volume":"22","author":"Seventer","year":"2006","journal-title":"Current Medical Research and Opinion"},{"issue":"8","key":"10.1002\/14651858.CD007076.pub3-BIB0046|cit46","doi-asserted-by":"publisher","first-page":"1082","DOI":"10.1111\/j.1468-1331.2010.02979.x","article-title":"Pregabalin in the treatment of post-traumatic peripheral neuropathic pain: a randomized double-blind trial","volume":"17","author":"Seventer","year":"2010","journal-title":"European Journal of Neurology"},{"key":"10.1002\/14651858.CD007076.pub3-BIB0047|cit47","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1186\/1477-7525-9-17","article-title":"Relationships between changes in pain severity and other patient-reported outcomes: an analysis in patients with posttraumatic peripheral neuropathic pain","volume":"9","author":"Seventer","year":"2011","journal-title":"Health and Quality of Life Outcomes"},{"issue":"12","key":"10.1002\/14651858.CD007076.pub3-BIB0048|cit48","doi-asserted-by":"publisher","first-page":"3253","DOI":"10.2337\/dc14-1044","article-title":"Efficacy and safety of mirogabalin (DS-5565) for the treatment of diabetic peripheral neuropathic pain: a randomized, double-blind, placebo- and active comparator-controlled, adaptive proof-of-concept phase 2 study","volume":"37","author":"Vinik","year":"2014","journal-title":"Diabetes Care"},{"issue":"10","key":"10.1002\/14651858.CD007076.pub3-BIB0049|cit49","doi-asserted-by":"publisher","first-page":"2013","DOI":"10.1097\/j.pain.0000000000000263","article-title":"A randomized double-blind, placebo-, and active-controlled study of T-type calcium channel blocker ABT-639 in patients with diabetic peripheral neuropathic pain","volume":"156","author":"Ziegler","year":"2015","journal-title":"Pain"},{"key":"10.1002\/14651858.CD007076.pub3-BIB0050|cit50","unstructured":"Anon A randomized placebo-controlled trial of the efficacy and tolerability of flexibly dosed pregabalin in the treatment of cancer-induced bone pain. 12 December 2014 pfizer.com\/science\/research_clinical_trials\/trial_results (accessed 2 May 2018)"},{"key":"10.1002\/14651858.CD007076.pub3-BIB0051|cit51","unstructured":"Anon A methodology study to assess the ability of a randomized, double-blind, placebo-controlled, two period crossover study to detect the effect of pregabalin in post-traumatic neuropathic pain patients. 2014 pfizer.com\/science\/research_clinical_trials\/trial_results (accessed 12 June 2017)"},{"key":"10.1002\/14651858.CD007076.pub3-BIB0052|cit52","unstructured":"Anon A randomized, double-blind, placebo-controlled, parallel group study of the efficacy and safety of concomitant administration of celecoxib and pregabalin compared with celecoxib monotherapy, in patients with chronic low back pain having a neuropathic component. 4 July 2016 pfizer.com\/science\/research_clinical_trials\/trial_results (accessed 12 June 2017)"},{"issue":"12","key":"10.1002\/14651858.CD007076.pub3-BIB0053|cit53","doi-asserted-by":"publisher","first-page":"2451","DOI":"10.2337\/dc12-0656","article-title":"Randomized, placebo-controlled comparison of amitriptyline, duloxetine, and pregabalin in patients with chronic diabetic peripheral neuropathic pain: impact on pain, polysomnographic sleep, daytime functioning, and quality of life","volume":"35","author":"Boyle","year":"2012","journal-title":"Diabetes Care"},{"key":"10.1002\/14651858.CD007076.pub3-BIB0054|cit54","doi-asserted-by":"crossref","unstructured":"Shende SD (Principal Investigator) A prospective, controlled, randomized, double blind, comparative, parallel, 2-arm study to evaluate the efficacy and safety of Epalrestat (150 mg) compared to Pregabalin (600 mg) in patients suffering from painful diabetic peripheral neuropathy ctri.nic.in\/Clinicaltrials\/pmaindet2.php?trialid=6445 (accessed 13 February 2018)","DOI":"10.7860\/JCDR\/2018\/32716.11444"},{"issue":"12","key":"10.1002\/14651858.CD007076.pub3-BIB0055|cit55","doi-asserted-by":"publisher","first-page":"1111","DOI":"10.1056\/NEJMoa1614292","article-title":"Trial of pregabalin for acute and chronic sciatica","volume":"376","author":"Mathieson","year":"2017","journal-title":"New England Journal of Medicine"},{"key":"10.1002\/14651858.CD007076.pub3-BIB0056|cit56","unstructured":"NCT00787462 Evaluation of pregabalin in idiopathic small fiber neuropathy clinicaltrials.gov\/ct2\/show\/NCT00787462 (accessed 13 February 2018)"},{"key":"10.1002\/14651858.CD007076.pub3-BIB0057|cit57","unstructured":"NCT00908375 Efficacy of pregabalin in patients with radicular pain clinicaltrials.gov\/ct2\/show\/NCT00908375 (accessed 13 February 2018)"},{"key":"10.1002\/14651858.CD007076.pub3-BIB0058|cit58","unstructured":"NCT01058642 A phase 2A, randomized, blinded, placebo- and active-controlled, 2-period crossover study to assess the analgesic efficacy, safety, and tolerability of ADL5747 in subjects with postherpetic neuralgia clinicaltrials.gov\/ct2\/show\/NCT01058642 (accessed 13 February 2018)"},{"key":"10.1002\/14651858.CD007076.pub3-BIB0059|cit59","unstructured":"NCT01089556 Use of duloxetine or pregabalin in monotherapy versus combination therapy of both drugs in patients with painful diabetic neuropathy: \"The COMBO - DN (COmbination vs Monotherapy of pregaBalin and dulOxetine in Diabetic Neuropathy) Study\" clinicaltrials.gov\/ct2\/show\/NCT01089556 (accessed 13 February 2018)"},{"key":"10.1002\/14651858.CD007076.pub3-BIB0060|cit60","unstructured":"NCT01180608 Functional imaging of the therapeutic effect of pregabalin in treatment for neuropathic pain in patients with diabetic polyneuropathy using proton MR spectroscopy clinicaltrials.gov\/ct2\/show\/NCT01180608 (accessed 13 February 2018)"},{"key":"10.1002\/14651858.CD007076.pub3-BIB0061|cit61","unstructured":"NCT01928381 A randomized, double-blind, placebo-controlled crossover study to evaluate the preliminary efficacy of AZD5213 in combination with pregabalin in subjects with painful diabetic neuropathy and good pain reporting ability clinicaltrials.gov\/ct2\/show\/NCT01928381 (accessed 13 February 2018)"},{"key":"10.1002\/14651858.CD007076.pub3-BIB0062|cit62","unstructured":"NCT02215252 A randomized double blind placebo and active controlled parallel group phase 2 study to evaluate PF-05089771 as a monotherapy and as an add-on to pregabalin for the treatment of painful diabetic peripheral neuropathy clinicaltrials.gov\/ct2\/show\/record\/NCT02215252 (accessed 2 May 2018)"},{"key":"10.1002\/14651858.CD007076.pub3-BIB0063|cit63","unstructured":"NCT02372578 A phase 2a randomized, double-blind, multicenter, placebo and active controlled study to assess analgesic efficacy and safety of ASP3662 in subjects with painful diabetic peripheral neuropathy clinicaltrials.gov\/ct2\/show\/NCT02372578 (accessed 13 February 2018)"},{"issue":"3","key":"10.1002\/14651858.CD007076.pub3-BIB0064|cit64","first-page":"192","article-title":"Evaluation of the efficacy and safety of pregabalin, venlafaxine, and carbamazepine in patients with painful diabetic peripheral neuropathy. A randomized, double-blind trial","volume":"19","author":"Razazian","year":"2014","journal-title":"Neurosciences (Riyadh)"},{"issue":"4","key":"10.1002\/14651858.CD007076.pub3-BIB0065|cit65","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1007\/s10195-009-0077-z","article-title":"Pregabalin, celecoxib, and their combination for treatment of chronic low-back pain","volume":"10","author":"Roman\u00f2","year":"2009","journal-title":"Journal of Orthopaedics and Traumatology"},{"issue":"1-2","key":"10.1002\/14651858.CD007076.pub3-BIB0066|cit66","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1016\/j.pain.2007.06.033","article-title":"Pregabalin in patients with central neuropathic pain: a randomized, double-blind, placebo-controlled trial of a flexible-dose regimen","volume":"136","author":"Vranken","year":"2008","journal-title":"Pain"},{"key":"10.1002\/14651858.CD007076.pub3-BIB0067|cit67","unstructured":"Anon Comparison of the therapeutic efficacy of pregabalin and duloxetine in peripheral neuropathy induced by taxanes containing chemotherapy regimens in women with breast cancer, a randomized clinical trial. 2016 who.int\/trialsearch\/Trial2.aspx?TrialID=IRCT201602112027N5 (accessed 13 February 2018)"},{"key":"10.1002\/14651858.CD007076.pub3-BIB0068|cit68","unstructured":"NCT00838799 A randomized, double-blind, placebo- and active-controlled study of the safety and efficacy of RGH-896 in patients with diabetic peripheral neuropathic pain clinicaltrials.gov\/ct2\/show\/NCT00838799 (accessed 13 February 2018)"},{"key":"10.1002\/14651858.CD007076.pub3-BIB0069|cit69","unstructured":"NCT01314222 A randomized, multicenter, double-blind, placebo- and active-controlled, cross-over study of the efficacy and safety of BMS-954561 in patients with diabetic peripheral neuropathic pain (DPNP) clinicaltrials.gov\/ct2\/show\/ NCT01314222 (accessed 13 February 2018)"},{"key":"10.1002\/14651858.CD007076.pub3-BIB0070|cit70","unstructured":"NCT01479556 Assessment of pregabalin efficacy for the treatment and prevention of at-level non-evoked and evoked spinal cord injury neuropathic pain clinicaltrials.gov\/ct2\/show\/NCT01479556 (accessed 13 February 2018)"},{"key":"10.1002\/14651858.CD007076.pub3-BIB0071|cit71","unstructured":"NCT01504412 An Asian, phase 2, multicenter, randomized, double-blind, placebo- and pregabalin-controlled, dose-finding study of DS-5565 in patients with pain associated with diabetic peripheral neuropathy clinicaltrials.gov\/ct2\/show\/NCT01504412 (accessed 13 February 2018)"},{"key":"10.1002\/14651858.CD007076.pub3-BIB0072|cit72","unstructured":"NCT01688947 A phase 2, randomized, double-blind, placebo- and active-controlled, parallel-group, multicenter study evaluating the analgesic efficacy and safety of V116517 in subjects with moderate to severe chronic pain due to postherpetic neuralgia (PHN) clinicaltrials.gov\/ct2\/show\/NCT01688947 (accessed 13 February 2018)"},{"key":"10.1002\/14651858.CD007076.pub3-BIB0073|cit73","unstructured":"NCT01939366 Efficacy, safety and tolerability of multiple doses of oral cebranopadol in subjects with moderate to severe chronic pain due to diabetic peripheral neuropathy clinicaltrials.gov\/ct2\/show\/NCT01939366 (accessed 13 February 2018)"},{"key":"10.1002\/14651858.CD007076.pub3-BIB0074|cit74","unstructured":"NCT02927951 A randomized, double-blind, placebo-controlled, cross-over study on the effect of pregabalin on pain related to walking in patients with diabetic peripheral neuropathy clinicaltrials.gov\/ct2\/show\/NCT02927951 (accessed 13 February 2018)"},{"key":"10.1002\/14651858.CD007076.pub3-BIB0075|cit75","unstructured":"NCT01869569 Effect of pregabalin in patients with radiation-induced peripheral neuropathic pain: a randomized double-blind placebo-controlled trial clinicaltrials.gov\/show\/NCT01869569 (accessed 13 February 2018)"},{"key":"10.1002\/14651858.CD007076.pub3-BIB0076|cit76","unstructured":"NCT02394951 Investigation of somatosensory predictors of response to pregabalin in painful chemotherapy-induced peripheral neuropathy (CIPN) clinicaltrials.gov\/ct2\/show\/NCT02394951 (accessed 12 June 2017)"},{"key":"10.1002\/14651858.CD007076.pub3-BIB0077|cit77","unstructured":"NCT02417935 A Japan post-marketing, randomized, double-blind, parallel-group, flexible dose comparative study to assess the non-inferiority of duloxetine compared with pregabalin in patients with diabetic peripheral neuropathic pain clinicaltrials.gov\/ct2\/show\/NCT02417935 (accessed 12 June 2017)"},{"key":"10.1002\/14651858.CD007076.pub3-BIB0078|cit78","unstructured":"NCT02607254 Efficacy and safety of pregabalin in treatment of neuropathic pain in patients with idiopathic small fiber neuropathy clinicaltrials.gov\/show\/NCT02607254 (accessed 18 February 2018)"},{"key":"10.1002\/14651858.CD007076.pub3-BIB0079|cit79","unstructured":"NCT02868801 Efficacy and safety of pregabalin sustained release tablet for postherpetic neuralgia - a multicenter, randomized, double-blind, placebo-controlled trial clinicaltrials.gov\/ct2\/show\/NCT02868801 (accessed 13 February 2018)"},{"key":"10.1002\/14651858.CD007076.pub3-BIB0080|cit80","unstructured":"NCT03276689 'Fix the Dysfunction' concept for mechanism-based pharmacological treatment of neuropathic pain by drug clinicaltrials.gov\/ct2\/show\/NCT03276689 (accessed 2 May 2018)"},{"issue":"2","key":"10.1002\/14651858.CD007076.pub3-BIB0081|cit81","doi-asserted-by":"publisher","first-page":"1102","DOI":"10.1016\/j.ijcard.2012.11.048","article-title":"Random error in cardiovascular meta-analyses: how common are false positive and false negative results?","volume":"168","author":"AlBalawi","year":"2013","journal-title":"International Journal of Cardiology"},{"issue":"1","key":"10.1002\/14651858.CD007076.pub3-BIB0082|cit82","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/S1474-4422(11)70281-2","article-title":"Chronic pain: genes, plasticity, and phenotypes","volume":"11","author":"Baron","year":"2012","journal-title":"Lancet Neurology"},{"issue":"2","key":"10.1002\/14651858.CD007076.pub3-BIB0083|cit83","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1097\/j.pain.0000000000000753","article-title":"Peripheral neuropathic pain: a mechanism-related organizing principle based on sensory profiles","volume":"158","author":"Baron","year":"2017","journal-title":"Pain"},{"issue":"3","key":"10.1002\/14651858.CD007076.pub3-BIB0084|cit84","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1016\/j.jpain.2003.12.004","article-title":"Clinical characteristics and economic costs of patients with painful neuropathic disorders","volume":"5","author":"Berger","year":"2004","journal-title":"Journal of Pain"},{"issue":"1","key":"10.1002\/14651858.CD007076.pub3-BIB0085|cit85","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1111\/j.1533-2500.2008.00244.x","article-title":"Clinical and economic characteristics of patients with painful neuropathic disorders in Germany","volume":"9","author":"Berger","year":"2009","journal-title":"Pain Practice"},{"key":"10.1002\/14651858.CD007076.pub3-BIB0086|cit86","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1186\/1471-2377-12-8","article-title":"Clinical characteristics and patterns of healthcare utilization in patients with painful neuropathic disorders in UK general practice: a retrospective cohort study","volume":"12","author":"Berger","year":"2012","journal-title":"BMC Neurology"},{"issue":"3","key":"10.1002\/14651858.CD007076.pub3-BIB0087|cit87","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1016\/j.pain.2007.08.013","article-title":"Prevalence of chronic pain with neuropathic characteristics in the general population","volume":"136","author":"Bouhassira","year":"2008","journal-title":"Pain"},{"issue":"1","key":"10.1002\/14651858.CD007076.pub3-BIB0088|cit88","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1093\/ije\/dyn188","article-title":"Apparently conclusive meta-analyses may be inconclusive - trial sequential analysis adjustment of random error risk due to repetitive testing of accumulating data in apparently conclusive neonatal meta-analyses","volume":"38","author":"Brok","year":"2009","journal-title":"International Journal of Epidemiology"},{"issue":"7","key":"10.1002\/14651858.CD007076.pub3-BIB0089|cit89","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1016\/S1474-4422(12)70134-5","article-title":"The role of the immune system in the generation of neuropathic pain","volume":"11","author":"Calvo","year":"2012","journal-title":"Lancet Neurology"},{"issue":"7","key":"10.1002\/14651858.CD007076.pub3-BIB0090|cit90","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD008943.pub2","article-title":"Combination pharmacotherapy for the treatment of neuropathic pain in adults","author":"Chaparro","year":"2012","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"10.1002\/14651858.CD007076.pub3-BIB0091|cit91","doi-asserted-by":"publisher","first-page":"17002","DOI":"10.1038\/nrdp.2017.2","article-title":"Neuropathic pain","volume":"3","author":"Colloca","year":"2017","journal-title":"Nature Reviews Disease Primers"},{"issue":"4","key":"10.1002\/14651858.CD007076.pub3-BIB0092|cit92","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1111\/j.1369-1600.2012.00468.x","article-title":"Pregabalin reduces cocaine self-administration and relapse to cocaine seeking in the rat","volume":"18","author":"Guglielmo","year":"2013","journal-title":"Addiction Biology"},{"key":"10.1002\/14651858.CD007076.pub3-BIB0093|cit93","doi-asserted-by":"publisher","first-page":"f2304","DOI":"10.1136\/bmj.f2304","article-title":"Influence of trial sample size on treatment effect estimates: meta-epidemiological study","volume":"346","author":"Dechartres","year":"2013","journal-title":"BMJ"},{"key":"10.1002\/14651858.CD007076.pub3-BIB0094|cit94","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1001\/jama.2014.8166","article-title":"Association between analytic strategy and estimates of treatment outcomes in meta-analyses","volume":"312","author":"Dechartres","year":"2014","journal-title":"JAMA"},{"issue":"11","key":"10.1002\/14651858.CD007076.pub3-BIB0095|cit95","doi-asserted-by":"publisher","first-page":"2263","DOI":"10.1016\/j.pain.2014.08.014","article-title":"The effect of oxcarbazepine in peripheral neuropathic pain depends on pain phenotype: a randomised, double-blind, placebo-controlled phenotype-stratified study","volume":"155","author":"Demant","year":"2014","journal-title":"Pain"},{"issue":"9","key":"10.1002\/14651858.CD007076.pub3-BIB0096|cit96","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD010111","article-title":"Topical capsaicin (low concentration) for chronic neuropathic pain in adults","author":"Derry","year":"2012","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"7","key":"10.1002\/14651858.CD007076.pub3-BIB0097|cit97","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD010958.pub2","article-title":"Topical lidocaine for neuropathic pain in adults","author":"Derry","year":"2014","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"9","key":"10.1002\/14651858.CD007076.pub3-BIB0098|cit98","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD011790.pub2","article-title":"Pregabalin for pain in fibromyalgia in adults","author":"Derry","year":"2016","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"10","key":"10.1002\/14651858.CD007076.pub3-BIB0099|cit99","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD011605.pub2","article-title":"Fentanyl for neuropathic pain in adults","author":"Derry","year":"2016","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"1","key":"10.1002\/14651858.CD007076.pub3-BIB0100|cit100","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD007393.pub4","article-title":"Topical capsaicin (high concentration) for chronic neuropathic pain in adults","author":"Derry","year":"2017","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"2","key":"10.1002\/14651858.CD007076.pub3-BIB0101|cit101","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1016\/j.jpain.2007.09.005","article-title":"Interpreting the clinical importance of treatment outcomes in chronic pain clinical trials: IMMPACT recommendations","volume":"9","author":"Dworkin","year":"2008","journal-title":"Journal of Pain"},{"issue":"11","key":"10.1002\/14651858.CD007076.pub3-BIB0102|cit102","doi-asserted-by":"publisher","first-page":"2249","DOI":"10.1016\/j.pain.2013.06.004","article-title":"Interventional management of neuropathic pain: NeuPSIG recommendations","volume":"154","author":"Dworkin","year":"2013","journal-title":"Pain"},{"issue":"6","key":"10.1002\/14651858.CD007076.pub3-BIB0103|cit103","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1016\/S0885-3924(99)00093-7","article-title":"Reporting of adverse effects in clinical trials should be improved: lessons from acute postoperative pain","volume":"18","author":"Edwards","year":"1999","journal-title":"Journal of Pain and Symptom Management"},{"issue":"3","key":"10.1002\/14651858.CD007076.pub3-BIB0104|cit104","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1016\/j.pain.2004.07.004","article-title":"Efficacy and safety of valdecoxib for treatment of osteoarthritis and rheumatoid arthritis: systematic review of randomised controlled trials","volume":"111","author":"Edwards","year":"2004","journal-title":"Pain"},{"issue":"7","key":"10.1002\/14651858.CD007076.pub3-BIB0105|cit105","doi-asserted-by":"publisher","first-page":"1284","DOI":"10.1097\/j.pain.0000000000000173","article-title":"Perioperative use of pregabalin for acute pain - a systematic review and meta-analysis","volume":"156","author":"Eipe","year":"2015","journal-title":"Pain"},{"issue":"1","key":"10.1002\/14651858.CD007076.pub3-BIB0106|cit106","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1093\/ije\/31.1.140","article-title":"Meta-analyses involving cross-over trials: methodological issues","volume":"31","author":"Elbourne","year":"2002","journal-title":"International Journal of Epidemiology"},{"key":"10.1002\/14651858.CD007076.pub3-BIB0107|cit107","unstructured":"Electronic Medicines Compendium emc.medicines.org.uk\/"},{"key":"10.1002\/14651858.CD007076.pub3-BIB0108|cit108","unstructured":"Effective Practice Organisation of Care (EPOC) 23. Worksheets for preparing a Summary of Findings using GRADE. Resources for review authors Oslo: Norwegian Knowledge Centre for the Health Services. Available at: epoc.cochrane.org\/epoc-specific-resources-review-authors"},{"issue":"4","key":"10.1002\/14651858.CD007076.pub3-BIB0109|cit109","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1007\/s40265-017-0700-x","article-title":"Abuse and misuse of pregabalin and gabapentin","volume":"77","author":"Evoy","year":"2017","journal-title":"Drugs"},{"key":"10.1002\/14651858.CD007076.pub3-BIB0110|cit110","doi-asserted-by":"publisher","first-page":"3714","DOI":"10.1073\/pnas.1618569114","article-title":"Meta-assessment of bias in science","volume":"114","author":"Fanelli","year":"2017","journal-title":"PNAS"},{"issue":"7","key":"10.1002\/14651858.CD007076.pub3-BIB0111|cit111","doi-asserted-by":"publisher","first-page":"953","DOI":"10.1002\/j.1532-2149.2012.00282.x","article-title":"Neuropathic pain needs systematic classification","volume":"17","author":"Finnerup","year":"2013","journal-title":"European Journal of Pain"},{"issue":"2","key":"10.1002\/14651858.CD007076.pub3-BIB0112|cit112","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1016\/S1474-4422(14)70251-0","article-title":"Pharmacotherapy for neuropathic pain in adults: a systematic review and meta-analysis","volume":"14","author":"Finnerup","year":"2015","journal-title":"Lancet Neurology"},{"key":"10.1002\/14651858.CD007076.pub3-BIB0113|cit113","first-page":"257","article-title":"Predictors of placebo response in peripheral neuropathic pain: insights from pregabalin clinical trials","volume":"8","author":"Freeman","year":"2015","journal-title":"Journal of Pain"},{"issue":"1","key":"10.1002\/14651858.CD007076.pub3-BIB0114|cit114","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1016\/j.maturitas.2014.06.013","article-title":"Treating chronic non-cancer pain in older people - more questions than answers?","volume":"79","author":"Gaskell","year":"2014","journal-title":"Maturitas"},{"issue":"7","key":"10.1002\/14651858.CD007076.pub3-BIB0115|cit115","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD010692.pub3","article-title":"Oxycodone for neuropathic pain in adults","author":"Gaskell","year":"2016","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"3","key":"10.1002\/14651858.CD007076.pub3-BIB0116|cit116","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD008261.pub2","article-title":"Pharmacological interventions for prevention or treatment of postoperative pain in people undergoing laparoscopic cholecystectomy","author":"Gurusamy","year":"2014","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"1","key":"10.1002\/14651858.CD007076.pub3-BIB0117|cit117","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1111\/j.1399-6576.2007.01486.x","article-title":"Prevalence of self-reported neuropathic pain and impact on quality of life: a prospective representative survey","volume":"52","author":"Gustorff","year":"2008","journal-title":"Acta Anaesthesiologica Scandinavica"},{"issue":"12","key":"10.1002\/14651858.CD007076.pub3-BIB0118|cit118","doi-asserted-by":"publisher","first-page":"1294","DOI":"10.1016\/j.jclinepi.2011.03.017","article-title":"GRADE guidelines: 7. Rating the quality of evidence - inconsistency","volume":"64","author":"Guyatt","year":"2011","journal-title":"Journal of Cinical Epidemiology"},{"key":"10.1002\/14651858.CD007076.pub3-BIB0119|cit119","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1016\/j.jclinepi.2012.01.006","article-title":"GRADE guidelines: 11. Making an overall rating of confidence in effect estimates for a single outcome and for all outcomes","volume":"66","author":"Guyatt","year":"2013","journal-title":"Journal of Clinical Epidemiology"},{"key":"10.1002\/14651858.CD007076.pub3-BIB0120|cit120","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1016\/j.jclinepi.2012.01.012","article-title":"GRADE guidelines: 12. Preparing summary of findings tables - binary outcomes","volume":"66","author":"Guyatt","year":"2013","journal-title":"Journal of Clinical Epidemiology"},{"key":"10.1002\/14651858.CD007076.pub3-BIB0121|cit121","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1186\/1471-2296-9-26","article-title":"Primary care incidence and treatment of four neuropathic pain conditions: a descriptive study, 2002-2005","volume":"9","author":"Hall","year":"2008","journal-title":"BMC Family Practice"},{"issue":"2","key":"10.1002\/14651858.CD007076.pub3-BIB0122|cit122","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1002\/cpt.19","article-title":"Individualized pharmacological treatment of neuropathic pain","volume":"97","author":"Helfert","year":"2015","journal-title":"Clinical Pharmacology and Therapeutics"},{"key":"10.1002\/14651858.CD007076.pub3-BIB0123|cit123","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","article-title":"Measuring inconsistency in meta-analyses","volume":"327","author":"Higgins","year":"2003","journal-title":"BMJ"},{"key":"10.1002\/14651858.CD007076.pub3-BIB0124|cit124","unstructured":"Higgins JPT Altman DG Sterne JAC (editors) Chapter 8: Assessing risk of bias in included studies. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011 Available from handbook.cochrane.org"},{"issue":"2","key":"10.1002\/14651858.CD007076.pub3-BIB0125|cit125","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1016\/j.pain.2009.09.017","article-title":"How do changes in pain severity levels correspond to changes in health status 3 and function in patients with painful diabetic peripheral neuropathy?","volume":"149","author":"Hoffman","year":"2010","journal-title":"Pain"},{"issue":"4","key":"10.1002\/14651858.CD007076.pub3-BIB0126|cit126","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1001\/jama.285.4.437","article-title":"Completeness of safety reporting in randomized trials: an evaluation of 7 medical areas","volume":"285","author":"Ioannidis","year":"2001","journal-title":"Journal of the American Medical Association"},{"issue":"1","key":"10.1002\/14651858.CD007076.pub3-BIB0127|cit127","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/0197-2456(95)00134-4","article-title":"Assessing the quality of reports of randomized clinical trials: is blinding necessary?","volume":"17","author":"Jadad","year":"1996","journal-title":"Controlled Clinical Trials"},{"key":"10.1002\/14651858.CD007076.pub3-BIB0128|cit128","doi-asserted-by":"crossref","unstructured":"Jensen TS Baron R Haanp\u00e4\u00e4 M Kalso E Loeser JD Rice AS A new definition of neuropathic pain Pain 2011 2204 5 10.1016\/j.pain.2011.06.017","DOI":"10.1016\/j.pain.2011.06.017"},{"issue":"8","key":"10.1002\/14651858.CD007076.pub3-BIB0129|cit129","doi-asserted-by":"publisher","first-page":"1059","DOI":"10.1111\/j.1526-4637.2012.01427.x.","article-title":"Early pain reduction can predict treatment response: results of integrated efficacy analyses of a once-daily gastroretentive formulation of gabapentin in patients with postherpetic neuralgia","volume":"13","author":"Jensen","year":"2012","journal-title":"Pain Medicine"},{"key":"10.1002\/14651858.CD007076.pub3-BIB0130|cit130","doi-asserted-by":"publisher","first-page":"f7339","DOI":"10.1136\/bmj.f7339","article-title":"Drugs for neuropathic pain","volume":"347","author":"Kalso","year":"2013","journal-title":"BMJ"},{"key":"10.1002\/14651858.CD007076.pub3-BIB0131|cit131","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1186\/s13075-016-0972-7","article-title":"High correlation of VAS pain scores after 2 and 6 weeks of treatment with VAS pain scores at 12 weeks in randomised controlled trials in rheumatoid arthritis and osteoarthritis: meta-analysis and implications","volume":"18","author":"Karabis","year":"2016","journal-title":"Arthritis Research and Therapy"},{"issue":"5-6","key":"10.1002\/14651858.CD007076.pub3-BIB0132|cit132","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1159\/000110284","article-title":"Epidemiology and clinical features of idiopathic trigeminal neuralgia and glossopharyngeal neuralgia: similarities and differences, Rochester, Minnesota, 1945-1984","volume":"10","author":"Katusic","year":"1991","journal-title":"Neuroepidemiology"},{"issue":"5","key":"10.1002\/14651858.CD007076.pub3-BIB0133|cit133","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1016\/S0015-0282(16)58265-X","article-title":"Empirical evidence of bias in infertility research: overestimation of treatment effect in crossover trials using pregnancy as the outcome measure","volume":"65","author":"Khan","year":"1996","journal-title":"Fertility and Sterility"},{"issue":"1-3","key":"10.1002\/14651858.CD007076.pub3-BIB0134|cit134","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1016\/j.pain.2009.08.023","article-title":"Incidence of facial pain in the general population","volume":"147","author":"Koopman","year":"2009","journal-title":"Pain"},{"issue":"2","key":"10.1002\/14651858.CD007076.pub3-BIB0135|cit135","doi-asserted-by":"publisher","first-page":"224","DOI":"10.7326\/0003-4819-107-2-224","article-title":"Meta-analysis in clinical research","volume":"107","author":"L'Abb\u00e9","year":"1987","journal-title":"Annals of Internal Medicine"},{"issue":"1","key":"10.1002\/14651858.CD007076.pub3-BIB0136|cit136","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1007\/s00784-017-2272-2","article-title":"Oral pregabalin for acute pain relief after cervicofacial surgery: a systematic review","volume":"22","author":"Li\u00e9bana-Hermoso","year":"2018","journal-title":"Clinical Oral Investigations"},{"key":"10.1002\/14651858.CD007076.pub3-BIB0137|cit137","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1186\/1472-6904-1-3","article-title":"Reporting of adverse drug reactions in randomised controlled trials - a systematic survey","volume":"1","author":"Loke","year":"2001","journal-title":"BMC Clinical Pharmacology"},{"issue":"1","key":"10.1002\/14651858.CD007076.pub3-BIB0138|cit138","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD007115.pub3","article-title":"Duloxetine for treating painful neuropathy, chronic pain or fibromyalgia","author":"Lunn","year":"2014","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"10.1002\/14651858.CD007076.pub3-BIB0139|cit139","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1136\/bmj.311.7012.1047","article-title":"Anticonvulsant drugs for management of pain: a systematic review","volume":"311","author":"McQuay","year":"1995","journal-title":"BMJ"},{"key":"10.1002\/14651858.CD007076.pub3-BIB0140|cit140","article-title":"Chronic pain","volume-title":"Health Care Needs Assessment: The Epidemiologically Based Needs Assessment Reviews: Third Series","author":"McQuay","year":"2007"},{"issue":"3","key":"10.1002\/14651858.CD007076.pub3-BIB0141|cit141","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1016\/j.pain.2008.01.014","article-title":"Enriched enrolment with randomised withdrawal (EERW): time for a new look at clinical trial design in chronic pain","volume":"135","author":"McQuay","year":"2008","journal-title":"Pain"},{"key":"10.1002\/14651858.CD007076.pub3-BIB0142|cit142","doi-asserted-by":"crossref","first-page":"1896","DOI":"10.1016\/S0140-6736(99)04149-5","article-title":"Improving the quality of reports of meta-analyses of randomised controlled trials: the QUOROM statement. Quality of reporting of meta-analyses","volume":"354","author":"Moher","year":"1999","journal-title":"Lancet"},{"issue":"3","key":"10.1002\/14651858.CD007076.pub3-BIB0143|cit143","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1016\/S0304-3959(98)00140-7","article-title":"Size is everything - large amounts of information are needed to overcome random effects in estimating direction and magnitude of treatment effects","volume":"78","author":"Moore","year":"1998","journal-title":"Pain"},{"issue":"3","key":"10.1002\/14651858.CD007076.pub3-BIB0144|cit144","doi-asserted-by":"publisher","first-page":"322","DOI":"10.1016\/j.pain.2005.05.001","article-title":"Acute pain: individual patient meta-analysis shows the impact of different ways of analysing and presenting results","volume":"116","author":"Moore","year":"2005","journal-title":"Pain"},{"key":"10.1002\/14651858.CD007076.pub3-BIB0145|cit145","first-page":"15","article-title":"Managing potential publication bias","volume-title":"Systematic Reviews in Pain Research: Methodology Refined","author":"Moore","year":"2008"},{"issue":"3","key":"10.1002\/14651858.CD007076.pub3-BIB0146|cit146","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1016\/j.pain.2010.05.011","article-title":"\"Evidence\" in chronic pain - establishing best practice in the reporting of systematic reviews","volume":"150","author":"Moore","year":"2010","journal-title":"Pain"},{"issue":"3","key":"10.1002\/14651858.CD007076.pub3-BIB0147|cit147","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1016\/j.pain.2010.02.032","article-title":"Topical review: chronic low back pain analgesic studies - a methodological minefield","volume":"149","author":"Moore","year":"2010","journal-title":"Pain"},{"issue":"2","key":"10.1002\/14651858.CD007076.pub3-BIB0148|cit148","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1016\/j.pain.2010.02.039","article-title":"Fibromyalgia: moderate and substantial pain intensity reduction predicts improvement in other outcomes and substantial quality of life gain","volume":"149","author":"Moore","year":"2010","journal-title":"Pain"},{"issue":"3","key":"10.1002\/14651858.CD007076.pub3-BIB0149|cit149","doi-asserted-by":"publisher","first-page":"592","DOI":"10.1016\/j.pain.2010.07.013","article-title":"Numbers-needed-to-treat analyses - do timing, dropouts, and outcome matter? Pooled analysis of two randomized, placebo-controlled chronic low back pain trials","volume":"151","author":"Moore","year":"2010","journal-title":"Pain"},{"issue":"2","key":"10.1002\/14651858.CD007076.pub3-BIB0150|cit150","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1136\/ard.2009.107805","article-title":"Responder analysis for pain relief and numbers needed to treat in a meta-analysis of etoricoxib osteoarthritis trials: bridging a gap between clinical trials and clinical practice","volume":"69","author":"Moore","year":"2010","journal-title":"Annals of the Rheumatic Diseases"},{"issue":"2","key":"10.1002\/14651858.CD007076.pub3-BIB0151|cit151","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1016\/j.pain.2009.08.007","article-title":"Clinical effectiveness: an approach to clinical trial design more relevant to clinical practice, acknowledging the importance of individual differences","volume":"149","author":"Moore","year":"2010","journal-title":"Pain"},{"issue":"5","key":"10.1002\/14651858.CD007076.pub3-BIB0152|cit152","doi-asserted-by":"publisher","first-page":"982","DOI":"10.1016\/j.pain.2010.11.030","article-title":"Minimum efficacy criteria for comparisons between treatments using individual patient meta-analysis of acute pain trials: examples of etoricoxib, paracetamol, ibuprofen, and ibuprofen\/paracetamol combinations after third molar extraction","volume":"152","author":"Moore","year":"2011","journal-title":"Pain"},{"issue":"2","key":"10.1002\/14651858.CD007076.pub3-BIB0153|cit153","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1016\/j.pain.2011.10.004","article-title":"Estimate at your peril: imputation methods for patient withdrawal can bias efficacy outcomes in chronic pain trials using responder analyses","volume":"153","author":"Moore","year":"2012","journal-title":"Pain"},{"issue":"12","key":"10.1002\/14651858.CD007076.pub3-BIB0154|cit154","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD008242.pub2","article-title":"Amitriptyline for neuropathic pain and fibromyalgia in adults","author":"Moore","year":"2012","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD007076.pub3-BIB0155|cit155","doi-asserted-by":"publisher","first-page":"S77","DOI":"10.1016\/j.pain.2013.03.024","article-title":"What works for whom? Determining the efficacy and harm of treatments for pain","volume":"154","author":"Moore","year":"2013","journal-title":"Pain"},{"key":"10.1002\/14651858.CD007076.pub3-BIB0156|cit156","doi-asserted-by":"publisher","first-page":"f2690","DOI":"10.1136\/bmj.f2690","article-title":"Expect analgesic failure; pursue analgesic success","volume":"346","author":"Moore","year":"2013","journal-title":"BMJ"},{"issue":"4","key":"10.1002\/14651858.CD007076.pub3-BIB0157|cit157","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1111\/anae.12148","article-title":"Pain measures and cut-offs - 'no worse than mild pain' as a simple, universal outcome","volume":"68","author":"Moore","year":"2013","journal-title":"Anaesthesia"},{"issue":"1","key":"10.1002\/14651858.CD007076.pub3-BIB0158|cit158","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1111\/papr.12050","article-title":"The costs and consequences of adequately managed chronic non-cancer pain and chronic neuropathic pain","volume":"14","author":"Moore","year":"2014","journal-title":"Pain Practice"},{"issue":"1","key":"10.1002\/14651858.CD007076.pub3-BIB0159|cit159","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1002\/j.1532-2149.2013.00341.x","article-title":"Duloxetine use in chronic painful conditions - individual patient data responder analysis","volume":"18","author":"Moore","year":"2014","journal-title":"European Journal of Pain"},{"issue":"10","key":"10.1002\/14651858.CD007076.pub3-BIB0160|cit160","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD010902.pub2","article-title":"Oral nonsteroidal anti-inflammatory drugs for neuropathic pain","author":"Moore","year":"2015","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"7","key":"10.1002\/14651858.CD007076.pub3-BIB0161|cit161","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD008242.pub3","article-title":"Amitriptyline for neuropathic pain in adults","author":"Moore","year":"2015","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"8","key":"10.1002\/14651858.CD007076.pub3-BIB0162|cit162","doi-asserted-by":"publisher","first-page":"1382","DOI":"10.1097\/j.pain.0000000000000088","article-title":"Systematic review of enriched enrolment, randomised withdrawal trial designs in chronic pain: a new framework for design and reporting","volume":"156","author":"Moore","year":"2015","journal-title":"Pain"},{"issue":"6","key":"10.1002\/14651858.CD007076.pub3-BIB0163|cit163","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1155\/2014\/754693","article-title":"Pharmacological management of chronic neuropathic pain: revised consensus statement from the Canadian Pain Society","volume":"19","author":"Moulin","year":"2014","journal-title":"Pain Research & Management"},{"key":"10.1002\/14651858.CD007076.pub3-BIB0164|cit164","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1016\/j.jclinepi.2017.02.010","article-title":"Simple randomization did not protect against bias in smaller trials","volume":"84","author":"Nguyen","year":"2017","journal-title":"Journal of Clinical Epidemiology"},{"key":"10.1002\/14651858.CD007076.pub3-BIB0165|cit165","unstructured":"National Institute for Health and Care Excellence (NICE) Neuropathic pain - pharmacological management: the pharmacological management of neuropathic pain in adults in non-specialist settings, 2013 www.nice.org.uk\/guidance\/cg173"},{"key":"10.1002\/14651858.CD007076.pub3-BIB0166|cit166","doi-asserted-by":"publisher","first-page":"c3515","DOI":"10.1136\/bmj.c3515","article-title":"Small study effects in meta-analyses of osteoarthritis trials: meta-epidemiological study","volume":"341","author":"N\u00fcesch","year":"2010","journal-title":"BMJ"},{"key":"10.1002\/14651858.CD007076.pub3-BIB0167|cit167","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1111\/j.1526-4637.2009.00685.x","article-title":"Patient-centered perspective on treatment: outcomes in chronic pain","volume":"11","author":"O'Brien","year":"2010","journal-title":"Pain Medicine"},{"key":"10.1002\/14651858.CD007076.pub3-BIB0168|cit168","unstructured":"Cochrane Pain Palliative and Supportive Care Group PaPaS Author and Referee Guidance papas.cochrane.org\/papas-documents"},{"issue":"2","key":"10.1002\/14651858.CD007076.pub3-BIB0169|cit169","doi-asserted-by":"publisher","first-page":"e00205","DOI":"10.1002\/prp2.205","article-title":"Mechanisms of the gabapentinoids and \u03b1 2 \u03b4-1 calcium channel subunit in neuropathic pain","volume":"4","author":"Patel","year":"2016","journal-title":"Pharmacology Research & Perspectives"},{"key":"10.1002\/14651858.CD007076.pub3-BIB0170|cit170","unstructured":"NHS Digital Prescription Cost Analysis England 2017 NHS Digital, part of the Government Statistical Service,"},{"issue":"3","key":"10.1002\/14651858.CD007076.pub3-BIB0171|cit171","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1016\/j.amjopharm.2011.04.007","article-title":"Anorgasmia with gabapentin may be common in older patients","volume":"9","author":"Perloff","year":"2011","journal-title":"American Journal of Geriatric Pharmacotherapy"},{"key":"10.1002\/14651858.CD007076.pub3-BIB0172|cit172","unstructured":"Pharmacompass Pregabalin suppliers listed on PharmaCompass www.pharmacompass.com\/listed-active-pharmaceutical-ingredients\/pregabalin"},{"key":"10.1002\/14651858.CD007076.pub3-BIB0173|cit173","unstructured":"Pharma Marketing Top 50 pharmaceutical products by global sales http:\/\/www.pmlive.com\/top_pharma_list\/Top_50_pharmaceutical_products_by_global_sales"},{"key":"10.1002\/14651858.CD007076.pub3-BIB0174|cit174","doi-asserted-by":"crossref","first-page":"13","DOI":"10.2147\/JEP.S124391","article-title":"Review about gabapentin misuse, interactions, contraindications and side effects","volume":"9","author":"Quintero","year":"2017","journal-title":"Journal of Experimental Pharmacology"},{"key":"10.1002\/14651858.CD007076.pub3-BIB0175|cit175","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/0304-3959(94)90086-8","article-title":"Trigeminal neuralgia: the role of self-sustaining discharge in the trigeminal ganglion","volume":"56","author":"Rappaport","year":"1994","journal-title":"Pain"},{"issue":"2","key":"10.1002\/14651858.CD007076.pub3-BIB0176|cit176","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1016\/j.jpainsymman.2012.07.011","article-title":"Once-daily gastroretentive gabapentin for postherpetic neuralgia: integrated efficacy, time to onset of pain relief and safety analyses of data from two phase 3, multicenter, randomized, double-blind, placebo-controlled studies","volume":"46","author":"Rauck","year":"2013","journal-title":"Journal of Pain and Symptom Management"},{"key":"10.1002\/14651858.CD007076.pub3-BIB0177|cit177","unstructured":"Nordic Cochrane Centre, The Cochrane Collaboration Review Manager 5 2014"},{"key":"10.1002\/14651858.CD007076.pub3-BIB0178|cit178","doi-asserted-by":"publisher","first-page":"h2463","DOI":"10.1136\/bmj.h2463","article-title":"The knowledge system underpinning healthcare is not fit for purpose and must change","volume":"350","author":"Roberts","year":"2015","journal-title":"BMJ"},{"issue":"1","key":"10.1002\/14651858.CD007076.pub3-BIB0179|cit179","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1007\/s40263-015-0303-6","article-title":"Abuse potential of pregabalin: a systematic review","volume":"30","author":"Schjerning","year":"2016","journal-title":"CNS Drugs"},{"key":"10.1002\/14651858.CD007076.pub3-BIB0180|cit180","unstructured":"Sch\u00fcnemann HJ Oxman AD Higgins JPT Vist GE Glasziou P Guyatt GH Chapter 11: Presenting results and \u2018Summary of findings' tables. In: Higgins JPT, Green S (editors), Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011 Available from handbook.cochrane.org"},{"key":"10.1002\/14651858.CD007076.pub3-BIB0181|cit181","unstructured":"Sch\u00fcnemann HJ Oxman AD Vist GE Higgins JPT Deeks JJ Glasziou P Chapter 12: Interpreting results and drawing conclusions. In: Higgins JPT, Green S (editors), Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011 Available from handbook.cochrane.org"},{"issue":"9","key":"10.1002\/14651858.CD007076.pub3-BIB0182|cit182","doi-asserted-by":"publisher","first-page":"1308","DOI":"10.1016\/j.vaccine.2005.09.026","article-title":"The burden of herpes zoster: a prospective population based study","volume":"24","author":"Scott","year":"2006","journal-title":"Vaccine"},{"issue":"5","key":"10.1002\/14651858.CD007076.pub3-BIB0183|cit183","doi-asserted-by":"publisher","first-page":"811","DOI":"10.1097\/j.pain.0000000000001165","article-title":"Professionals underestimate patients' pain: a comprehensive review","volume":"159","author":"Seers","year":"2018","journal-title":"Pain"},{"key":"10.1002\/14651858.CD007076.pub3-BIB0184|cit184","unstructured":"Scottish Intercollegiate Guidelines Network SIGN Guideline 136 - Management of chronic pain. 2013 sign.ac.uk\/guidelines\/fulltext\/136\/contents.html (accessed 1 March 2017)"},{"issue":"7","key":"10.1002\/14651858.CD007076.pub3-BIB0185|cit185","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1016\/j.seizure.2003.12.006","article-title":"Epilepsy and erectile dysfunction: a review","volume":"13","author":"Smaldone","year":"2004","journal-title":"Seizure"},{"issue":"7","key":"10.1002\/14651858.CD007076.pub3-BIB0186|cit186","doi-asserted-by":"publisher","first-page":"1942","DOI":"10.1002\/art.37962","article-title":"Neuropathic features of joint pain: a community-based study","volume":"65","author":"Soni","year":"2013","journal-title":"Arthritis & Rheumatism"},{"issue":"5","key":"10.1002\/14651858.CD007076.pub3-BIB0187|cit187","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD011604.pub2","article-title":"Hydromorphone for neuropathic pain in adults","author":"Stannard","year":"2016","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"2","key":"10.1002\/14651858.CD007076.pub3-BIB0188|cit188","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1111\/j.1365-2125.2008.03200.x","article-title":"Enriched enrolment: definition and effects of enrichment and dose in trials of pregabalin and gabapentin in neuropathic pain. A systematic review","volume":"66","author":"Straube","year":"2008","journal-title":"British Journal of Clinical Pharmacology"},{"issue":"5","key":"10.1002\/14651858.CD007076.pub3-BIB0189|cit189","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD008183.pub2","article-title":"Single dose oral gabapentin for established acute postoperative pain in adults","author":"Straube","year":"2010","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"10.1002\/14651858.CD007076.pub3-BIB0190|cit190","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1186\/1471-2377-8-29","article-title":"Duloxetine for painful diabetic neuropathy and fibromyalgia pain: systematic review of randomised trials","volume":"8","author":"Sultan","year":"2008","journal-title":"BMC Neurology"},{"issue":"10","key":"10.1002\/14651858.CD007076.pub3-BIB0191|cit191","doi-asserted-by":"publisher","first-page":"e25491","DOI":"10.1371\/journal.pone.0025491","article-title":"The number of patients and events required to limit the risk of overestimation of intervention effects in meta-analysis - a simulation study","volume":"6","author":"Thorlund","year":"2011","journal-title":"PLoS One"},{"issue":"4","key":"10.1002\/14651858.CD007076.pub3-BIB0192|cit192","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/j.jpain.2005.11.008","article-title":"The epidemiology of chronic pain of predominantly neuropathic origin. Results from a general population survey","volume":"7","author":"Torrance","year":"2006","journal-title":"Journal of Pain"},{"issue":"7109","key":"10.1002\/14651858.CD007076.pub3-BIB0193|cit193","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1136\/bmj.315.7109.635","article-title":"Impact of covert duplicate publication on meta-analysis: a case study","volume":"315","author":"Tram\u00e8r","year":"1997","journal-title":"BMJ"},{"issue":"18","key":"10.1002\/14651858.CD007076.pub3-BIB0194|cit194","doi-asserted-by":"publisher","first-page":"1630","DOI":"10.1212\/01.wnl.0000282763.29778.59","article-title":"Neuropathic pain: redefinition and a grading system for clinical and research purposes","volume":"70","author":"Treede","year":"2008","journal-title":"Neurology"},{"issue":"3","key":"10.1002\/14651858.CD007076.pub3-BIB0195|cit195","doi-asserted-by":"publisher","first-page":"e59202","DOI":"10.1371\/journal.pone.0059202","article-title":"The impact of study size on meta-analyses: examination of underpowered studies in Cochrane Reviews","volume":"8","author":"Turner","year":"2013","journal-title":"PLoS One"},{"issue":"4","key":"10.1002\/14651858.CD007076.pub3-BIB0196|cit196","doi-asserted-by":"publisher","first-page":"654","DOI":"10.1016\/j.pain.2013.11.013","article-title":"Neuropathic pain in the general population: a systematic review of epidemiological studies","volume":"155","author":"Hecke","year":"2014","journal-title":"Pain"},{"issue":"9","key":"10.1002\/14651858.CD007076.pub3-BIB0197|cit197","doi-asserted-by":"publisher","first-page":"1454","DOI":"10.1016\/j.vaccine.2008.12.024","article-title":"Estimating the cost-effectiveness of vaccination against herpes zoster in England and Wales","volume":"27","author":"Hoek","year":"2009","journal-title":"Vaccine"},{"issue":"4","key":"10.1002\/14651858.CD007076.pub3-BIB0198|cit198","doi-asserted-by":"publisher","first-page":"638","DOI":"10.1016\/j.neuron.2012.02.008","article-title":"Deconstructing the neuropathic pain phenotype\u00a0to reveal neural mechanisms","volume":"73","author":"Hehn","year":"2012","journal-title":"Neuron"},{"issue":"9859","key":"10.1002\/14651858.CD007076.pub3-BIB0199|cit199","doi-asserted-by":"publisher","first-page":"2163","DOI":"10.1016\/S0140-6736(12)61729-2","article-title":"Years lived with disability (YLDs) for 1160 sequelae of 289 diseases and injuries 1990\u20132010: a systematic analysis for the Global Burden of Disease Study 2010","volume":"380","author":"Vos","year":"2012","journal-title":"Lancet"},{"issue":"11","key":"10.1002\/14651858.CD007076.pub3-BIB0200|cit200","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD010567.pub2","article-title":"Antiepileptic drugs for neuropathic pain and fibromyalgia - an overview of Cochrane reviews","author":"Wiffen","year":"2013","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"9","key":"10.1002\/14651858.CD007076.pub3-BIB0201|cit201","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD011603.pub2","article-title":"Buprenorphine for neuropathic pain in adults","author":"Wiffen","year":"2015","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"12","key":"10.1002\/14651858.CD007076.pub3-BIB0202|cit202","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD012227.pub2","article-title":"Paracetamol (acetaminophen) with or without codeine or dihydrocodeine for neuropathic pain in adults","author":"Wiffen","year":"2016","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"6","key":"10.1002\/14651858.CD007076.pub3-BIB0203|cit203","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD007938.pub4","article-title":"Gabapentin for chronic neuropathic pain in adults","author":"Wiffen","year":"2017","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"7","key":"10.1002\/14651858.CD007076.pub3-BIB0204|cit204","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD012637.pub2","article-title":"Oral paracetamol (acetaminophen) for cancer pain","author":"Wiffen","year":"2017","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"3","key":"10.1002\/14651858.CD007076.pub3-BIB0205|cit205","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD007076","article-title":"Pregabalin for acute and chronic pain in adults","author":"Moore","year":"2009","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"3","key":"10.1002\/14651858.CD007076.pub3-BIB0206|cit206","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD001133.pub2","article-title":"Anticonvulsant drugs for acute and chronic pain","author":"Wiffen","year":"2000","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"3","key":"10.1002\/14651858.CD007076.pub3-BIB0207|cit207","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD001133.pub2","article-title":"Anticonvulsant drugs for acute and chronic pain","author":"Wiffen","year":"2005","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"2","key":"10.1002\/14651858.CD007076.pub3-BIB0208|cit208","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD007076","article-title":"Pregabalin for acute and chronic pain in adults","author":"Wiffen","year":"2008","journal-title":"Cochrane Database of Systematic Reviews"}],"container-title":["Cochrane Database of Systematic Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cochranelibrary.com\/cdsr\/doi\/10.1002\/14651858.CD007076.pub3\/epdf\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,9]],"date-time":"2025-01-09T08:18:30Z","timestamp":1736410710000},"score":1,"resource":{"primary":{"URL":"http:\/\/doi.wiley.com\/10.1002\/14651858.CD007076.pub3"}},"subtitle":[],"editor":[{"name":"Cochrane Pain, Palliative and Supportive Care Group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2019,1,23]]},"references-count":208,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2019,5]]}},"URL":"https:\/\/doi.org\/10.1002\/14651858.cd007076.pub3","relation":{},"ISSN":["1465-1858"],"issn-type":[{"value":"1465-1858","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,1,23]]}}}